November 1, 2008Circulation Cardiovascular Quality and Outcomes
Effects of Ranolazine on Disease-Specific Health Status and Quality of Life Among Patients With Acute Coronary Syndromes
Key result
Ranolazine had a minimal effect on disease-specific health status and quality of life over 12 months among patients with non-ST-elevation acute coronary syndromes (P<0.05).
Why the study?
Does ranolazine improve disease-specific health status and quality of life in patients with non-ST-elevation acute coronary syndromes?
Population
6560 patients with non-ST-elevation acute coronary syndromes
Comparison
Ranolazine vs Placebo
Design
RCT, randomized, double-blind
Follow-up
12 months
Authors
Discussion
Loading...
Member takes
Implication
Ranolazine yields minimal QOL gains in ACS overall; does not support routine use but extends evidence for benefit limited to prior angina.
Study Design
Type
RCT (n=6,560)
Blinding
Double-blind
Randomization
randomized
Structured PICO
Does ranolazine improve disease-specific health status and quality of life in patients with non-ST-elevation acute coronary syndromes?
P
Population
6,560 patients with non-ST-elevation acute coronary syndromes evaluated for health status and quality of life over 12 months.
I
Intervention
Ranolazine
C
Comparator
Placebo
O
Outcome
Health status/quality of life evaluated at 4, 8, and 12 months after index hospitalization using the Seattle Angina Questionnaire, Rose dyspnea scale, SF-12, and EuroQol-5Dpatient reported
Main Result
p-value: p=<0.05
Ranolazine provides minimal overall quality of life improvement in patients with NSTE-ACS, but may offer modest benefits in angina frequency and quality of life for those with pre-existing angina.
Limitations
- Posthoc subgroup analysis
Cite This Study
Arnold et al. (2008) conducted an RCT in non-ST-elevation acute coronary syndromes (n=6,560). Ranolazine vs. placebo was evaluated on angina frequency and Seattle Angina Questionnaire-QOL (p=<0.05). Ranolazine had a minimal effect on disease-specific health status and quality of life over 12 months among patients with non-ST-elevation acute coronary syndromes (P<0.05).